UNSPSC 51334105: Perospirone hydrochloride

This classification denotes an anxiolytic with the molecular structure C23H30N4O2S.CLH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier, T884I76TMN chemically known as cis-n-(4-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)butyl)-1,2-cyclohexanedicarboximide hydrochloride, but more commonly known as perospirone hydrochloride, which bears US NIH Compound Identifier 115367. European Medicines Agency schedules Perospirone hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB20687.

Most nations, for tariff and trade purposes, schedule perospirone hydrochloride under HS 29341000 and SITC 51579. As of Q4 2014, PEROSPIRONE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. SMILES: C1CCC2C(C1)C(NS2)N3CCN(CC3)CCCCN4C(=O)[C@@H]5CCCC[C@@H]5C4=O.CL.

UNSPSC 51334105 Perospirone hydrochloride is a Commodity code that in practice encompasses a much broader range of pharmaceutical and health-related products than its narrow chemical name suggests. The recent state and local opportunities tagged under this code actually solicit naloxone and drug deactivation systems, generic multi-source pharmaceuticals and over-the-counter products through cooperative purchasing arrangements, and exploratory direct-to-manufacturer prescription programs. The issuing bodies include county health departments, state health and human services agencies, and multistate cooperative purchasing alliances serving state and local government facilities. The scope of work ranges from annual procurement of specific naloxone units and drug deactivation systems for community health support, to manufacturer supply agreements for generic pharmaceuticals distributed across multiple state and local facilities, to market-intelligence gathering for alternative pharmacy benefit models that bypass traditional pharmacy benefit managers and wholesalers.

Recent activity spans Florida, Texas, Minnesota, and Oregon. Seminole County, Florida issued IFB 60459723LAS in June 2026 seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with a response deadline of July 26, 2023 and quarterly deliveries to the county's Community Health Building. The Texas Health and Human Services Commission posted RFI HHS0017013 on April 3, 2026 to gather vendor capabilities for direct-to-manufacturer prescription programs serving self-insured employee health plans and state agencies. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, issued RFP S1070000015802 in January 2026 for generic multi-source pharmaceuticals and OTC products to be distributed across participating state and local facilities in Minnesota and Oregon, with proposals due March 26, 2026; awarded vendors must work through three authorized wholesalers and comply with cGMP and Drug Supply Chain Security Act certification requirements.